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We would like to thank Grill and Ringman [1] for their 
thoughtful response to our article [2] in which we made 
the case that both early-onset sporadic Alzheimer’s 
disease (AD) cases and known or suspected mutation 
carriers should generally be enrolled in clinical trials. 
Th  ere is consensus between our groups that excluding 
patients on the basis of age criteria alone is not valid. In 
regard to enrollment of patients with known or suspected 
autosomal dominant AD, the authors caution that these 
subjects may have a diﬀ  erent response or diﬀ  erent side-
eﬀ  ect proﬁ  le to a given intervention. We considered this 
possibility in our review; however, there are no human 
data and only scant preclinical data to support this hypo-
thesis. Available preclinical studies so far are insuﬃ   cient 
to support excluding all mutation carriers from all trials. 
Furthermore, it is likely that sporadic AD populations 
also contain between-subject diﬀ  erences that could pro-
duce diﬀ  erences in the magnitude or likelihood of res-
ponse to a treatment as well as diﬀ  erences in side eﬀ  ects. 
Random assignment of subjects in clinical trials is 
designed to counter such unknown diﬀ  erences. Although 
it is possible that preclinical development programs may 
uncover a rationale for excluding a particular mutation 
from a particular trial, our conclusion was that, until 
there are suﬃ   cient clinical trials that include mutation 
carriers alone or as a separate arm, these individuals 
should have the right to participate and should not be 
excluded categorically.
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